Letters to the Editor
Pneumonia and antibiotics
- Tom Perry, Bruce Markell, John Watson, Ken Harvey, Susie Rogers, Libby Roughead, David M. Merry, Keryn Christiansen
- Aust Prescr 1999;22:75-7
- 1 August 1999
- DOI: 10.18773/austprescr.1999.064
The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Editor, – I refer to the article 'Pneumonia in the Nineties' (Aust Prescr 1999;22:37-9). Is there any evidence from controlled trials (or other solid evidence) that the guidelines of the last 10 years have altered any outcome in community acquired pneumonia? What is the evidence that we should be substituting anything for amoxycillin routinely, even though many organisms associated with pathogenesis are not susceptible in vitro, if the clinical outcomes are similar?
Department of Pharmacology and Therapeutics and Department of Medicine
University of British Columbia
Dr K. Christiansen, the author of the article, comments:
Dr Perry is quite correct in that there have not been any controlled trials comparing the outcome for community acquired pneumonia for the various therapeutic guidelines that have been formulated over the last 10 years. The most relevant publication is of the medical outcomes and antibiotic costs associated with the use of the American Thoracic Society (ATS) guidelines in 864 outpatients with community acquired pneumonia. The study found that 62% of patients less than 60 years of age with no co-morbidity received therapy consistent with the ATS guidelines. There was no significant difference in medical outcome between those with consistent and inconsistent treatment. The cost was however significantly less (3-fold lower) for those in whom the ATS guidelines were followed. For patients more than 60 years of age or with co-morbidity, the ATS guidelines were not well adhered to with only 18% of patients receiving therapy as recommended with more than 50% of patients receiving a macrolide or tetracycline only. Not only were the costs greatly reduced (10-fold lower) but the medical outcome was the same with a trend to higher mortality and subsequent hospitalisation in the ATS consistent group.
The comment made by the authors was that the outcome supports the recommendation for macrolides for young patients without co-morbidity, but that there is no apparent benefit for the more costly ATS recommended therapy in patients with co-morbidity or older age. No comparisons were made with amoxycillin therapy.
Editor, – In the excellent recent articles on pneumonia and the appropriate use of antibiotics (Aust Prescr 1999;22:26-8 and 37-9), I was a little surprised, as a radiologist, to see the degree or pattern on x-rays of the chest did not come into the decisions of which antibiotics to use. My training taught me that lobar pneumonia needed a different group of antibiotics. Is this not still the case? Also, the radiological distribution of several large patches and 'more consolidation than illness of the patient', usually with a dry cough indicated mycoplasma.
Is the previously taught clinical maxim of 'if discharges are clear, it is likely to be a virus and if the discharge is thick, such as white, yellow or green then antibiotics are of benefit' still relevant?
Dr K. Christiansen, the author of the article, comments:
Although there are typical clinical presentations for lower respiratory tract infection by Streptococcus pneumoniae and the 'a typicals', Mycoplasma pneumoniae, Chlamydia pneumoniae and Legionella spp, there is much overlap and studies have shown that it is not possible to predict accurately the causative organism.2,3 Similarly, studies on the radio graphical appearances4,5,6 show that discrimination is not possible. More recently a direct comparison was made between chlamydial and pneumococcal pneumonia.7,8 An epidemic of Chlamydia pneumoniae occurred during a prospective study on community acquired pneumonia enabling the identification of 46 patients for whom a definite aetiology could be determined. This study confirmed that chlamydial pneumonia and pneumococcal pneumonia cannot be distinguished on clinical and radio graphical grounds. Given that the causative agent cannot be predicted accurately by either clinical presentation or radiological appearance antibiotic therapy cannot be decided on these parameters.
Editor, - In her paper 'Pneumonia in the Nineties' (Aust Prescr 1999;22:37-9), Keryn Christiansen states that 'penicillin was used for almost 4 decades before resistance was detected'. As a bright-eyed undergraduate in 1953, I can very clearly remember sitting in a cold lecture theatre at Sydney University enthralled by a stimulating young lecturer by the name of Ruthven Blackburn, who was trying to instil the fundamentals of medicine into what was most likely his initial class of dental students. I don't think I was alone in being impressed by the breadth, depth and detail of his knowledge as he recounted his experiences in the wards at nearby Royal Prince Alfred Hospital. Not only did Dr Blackburn present overwhelming evidence for the acquired resistance of certain strains of streptococci to penicillin, he successfully predicted that other nominated antibiotics would provoke the development of resistant organisms. He was later appointed to the chair of medicine at Sydney. If it has taken the rest of the world until the early 1980s to wake up to the phenomenon of antibiotic resistant organisms, then so be it. However, let us not overlook the visionary contribution made by this prescient academic and physician. By the same token, let us not blind ourselves to the possibility of future instances of mankind's failure to heed nature's warnings. What odds genetically engineered crops?
Editor, - I have been following your articles on initiatives to improve antibiotic use (Aust Prescr 1999;22:26-8). I agree that the profession needs to be more discriminating in its application of antibiotics even though we all know this sometimes runs counter to the treatment expectations of individual patients. There has been much talk regarding the appropriateness of antibiotics for otitis media. As an otolaryngologist, most of the patients that filter through to me have been under-treated with respect to their ear infections rather than over-treated. The same might be said for rhinosinusitis. I suspect we may see a return to surgical means of treatment such as myringotomy. The laser-assisted myringotomy, as an outpatient procedure under local anaesthetic, certainly shows promise. Myringotomy may actually improve the outcome of middle ear infection and reduce the incidence of otitis media with effusion, which many people believe is a form of 'antibioma'.
Whilst on the subject of antibiotic use and resistance, it has long concerned me that the indiscriminate use of common antibiotics in animal husbandry needs serious attention. Many organisms that have plagued mankind in the last 2000 years have apparently mutated from domestic and occasionally wild animals. High density farming practices with constant exposure to antibiotics in feedlots must surely be an excellent means of selecting resistant strains of bacteria just waiting to be transmitted into the human population. Can we be reassured that our efforts are being matched in animal husbandry? If not, I fear we are wasting our time.
David M. Merry
South Hobart, Tas.
Physician, Department of Pharmacology and Therapeutics and Department of Medicine, University of British Columbia, Canada
Radiologist, Newtown, N.S.W.
Dentist, Bathurst, N.S.W.
School of Public Health, La Trobe University, Melbourne
Inner South East Melbourne Division of General Practice
School of Pharmacy, University of South Australia, Adelaide
Otolaryngologist, South Hobart, Tas.
Clinical Microbiologist, Royal Perth Hospital, Perth